These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 26637737)

  • 1. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
    Malcovati L; Cazzola M
    Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
    Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
    Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDS overlap disorders and diagnostic boundaries.
    Tanaka TN; Bejar R
    Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal Hematopoiesis of Indeterminate Potential.
    Heuser M; Thol F; Ganser A
    Dtsch Arztebl Int; 2016 May; 113(18):317-22. PubMed ID: 27215596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICUS/CCUS/CHIP: basics & beyond.
    Jain M; Tripathi A
    Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
    DeZern AE; Malcovati L; Ebert BL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
    Valent P
    Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
    Osman A; Patel JL
    Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostics in unclear cytopenia-How and when do we screen for clonal hematopoiesis?].
    Haferlach C; Heuser M
    Inn Med (Heidelb); 2022 Nov; 63(11):1141-1147. PubMed ID: 36121473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
    Tang G; Medeiros LJ; Wang SA
    Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).
    Steensma DP
    Curr Hematol Malig Rep; 2019 Dec; 14(6):536-542. PubMed ID: 31696381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.
    Kwok B; Hall JM; Witte JS; Xu Y; Reddy P; Lin K; Flamholz R; Dabbas B; Yung A; Al-Hafidh J; Balmert E; Vaupel C; El Hader C; McGinniss MJ; Nahas SA; Kines J; Bejar R
    Blood; 2015 Nov; 126(21):2355-61. PubMed ID: 26429975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS.
    Valent P; Bain BJ; Bennett JM; Wimazal F; Sperr WR; Mufti G; Horny HP
    Leuk Res; 2012 Jan; 36(1):1-5. PubMed ID: 21920601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathologic challenges of clonal cytopenia of undetermined significance.
    Weinberg OK
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():82-85. PubMed ID: 34288451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.
    Barcellini W
    Expert Rev Hematol; 2017 Jul; 10(7):649-657. PubMed ID: 28586251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Special Education: Aplastic Anemia.
    Teramura M; Mizoguchi H
    Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
    Bejar R
    Curr Hematol Malig Rep; 2015 Sep; 10(3):282-91. PubMed ID: 26126599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.